Online inquiry

IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6909MR)

This product GTTS-WQ6909MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Alkaline phosphatase substitute gene. The antibody can be applied in Hypophosphatasia (HPP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000478.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 249
UniProt ID P05186
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6909MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3062MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ10921MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ8697MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ10218MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ14407MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ6312MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ135MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ3245MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW